

---

 Communications to the Editor
 

---

 ALDECALMYCIN, A NEW ANTIMICROBIAL  
 ANTIBIOTIC FROM *STREPTOMYCES*

Sir:

In the course of our screening from soil microorganisms for antibiotics, we have isolated a new antibiotic, aldecalmycin (**1**) from a culture broth of streptomycete. **1** shows antimicrobial activities against Gram-positive bacteria including methicillin-resistant *Staphylococcus aureus* (MRSA). In this communication, we report the production, isolation, physico-chemical and biological properties of **1**.

The producing microorganism was isolated from a soil sample collected at Setagaya-ku, Tokyo, Japan, which was classified as *Streptomyces*. A well-grown agar slant of the strain MJ147-72F6 was used to inoculate sixteen 500-ml Erlenmeyer flasks containing 110-ml of seed medium composed of galactose 2.0%, dextrin 2.0%, Bacto-soytone 1.0%, corn steep liquor 0.5%, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> 0.2% and CaCO<sub>3</sub> 0.2% (pH 7.4 before sterilization). The culture was incubated for 3 days at 27°C on a rotary shaker. Four hundred ml of this seed culture were transferred to four 20-liter jar fermenters each containing 12 liters of production medium consisting of glucose 2.0%, meat extract 3.0%, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> 0.6%, MgSO<sub>4</sub> 0.3%, K<sub>2</sub>HPO<sub>4</sub> 0.6%, CaCO<sub>3</sub> 0.2%

and Pronal 502 (Toho Chemical Industry) as an antifoaming reagent. The fermentation was continued for 3 days at 27°C with agitation at a rate of 200 rpm and aeration of 12 liters per minute.

The isolation of aldecalmycin is shown in Fig. 1 which was carried out using a silica gel column, Sephadex LH-20 column, preparative TLC, reverse phase HPLC and centrifugal partition chromatography. The antibiotic activity was monitored by bioassay using *Bacillus stearothermophilus*.

Physico-chemical properties of aldecalmycin (**1**) are summarized in Table 1. **1** was obtained as a white powder. The molecular formula of **1** was determined as C<sub>33</sub>H<sub>54</sub>O<sub>9</sub> by HRFAB-MS and elemental analysis. **1** shows characteristic UV absorption at 304 nm (E<sub>1%<sup>1</sup>cm</sub><sup>1</sup>, 395) in alkaline MeOH as shown in Fig. 2. The substance gave positive color reactions to 2,4-dinitrophenylhydrazine and molybdophosphoric acid-sulfuric acid reagents, and negative to ninhydrin and Rydon-Smith reagents. The structure of aldecalmycin (**1**) (Fig. 3) was determined by NMR spectral analysis of its derivative **2** because the NMR spectra of **1** were complicated by a presence of aldehyde group. The <sup>1</sup>H and <sup>13</sup>C NMR data of **2** are shown in Table 2. Aldecalmycin (**1**) is related to lydicamycin<sup>1)</sup> on its bicyclic ring system. Details of the structure determination of **1** and **2** will be reported later.

Table 1. Physico-chemical properties of aldecalmycin (**1**) and its derivative **2**.

	<b>1</b>	<b>2</b>
Appearance	White powder	White powder
Molecular formula	C <sub>33</sub> H <sub>54</sub> O <sub>9</sub>	C <sub>35</sub> H <sub>58</sub> O <sub>10</sub>
Elemental analysis		
Calcd:	C 65.64, H 9.18, O 25.18 (as C <sub>33</sub> H <sub>54</sub> O <sub>9</sub> · ½H <sub>2</sub> O)	
Found:	C 65.48, H 9.29, O 25.47	
FAB-MS ( <i>m/z</i> , (M-H) <sup>-</sup> )	593	637
HRFAB-MS ( <i>m/z</i> )		
Calcd:	593.3689 (as C <sub>33</sub> H <sub>53</sub> O <sub>9</sub> )	637.3952 (as C <sub>35</sub> H <sub>57</sub> O <sub>10</sub> )
Found:	593.3687 (M-H) <sup>-</sup>	637.3935 (M-H) <sup>-</sup>
UV λ <sub>max</sub> nm (E <sub>1%<sup>1</sup>cm</sub> <sup>1</sup> )		
in MeOH	272 (30), 299 (31)	End absorption
in HCl-MeOH	271 (24), 303 (sh, 13)	
in NaOH-MeOH	304 (395)	
IR ν <sub>max</sub> (KBr) cm <sup>-1</sup>	3430, 2960, 2910, 1694, 1626, 1456, 1379, 1074, 1038, 995	3440, 2960, 2910, 1698, 1636, 1456, 1379, 1134, 1076, 1019
TLC (Rf value) <sup>a</sup>	0.39	0.46

<sup>a</sup> Silica gel TLC (Merck Art. No. 5715) CHCl<sub>3</sub>-MeOH (20:3).

Fig. 1. Isolation and purification of aldecalmycin.




Fig. 2. The UV spectrum of aldecalmycin (1).





Fig. 3. The structure of aldecalmycin (1) and its derivative 2.

Table 2.  $^{13}\text{C}$  NMR data (100 MHz) and  $^1\text{H}$  NMR data (400 MHz) of the aldecalmycin derivative 2 in  $\text{CD}_3\text{OD}-\text{C}_6\text{D}_6$  (10:1).

Position	$^{13}\text{C}$	$^1\text{H}$	Position	$^{13}\text{C}$	$^1\text{H}$
16-Me	10.5	1.61	4	52.8	
14-Me	10.6	0.66	6'	62.4	3.88, 4.04
19	14.3	0.92	20 <sup>a</sup>	65.5	~3.8, ~3.9
4-Me	17.5	1.25	21 <sup>a</sup>	65.7	~3.8, ~3.9
18	21.6	1.99	4'	71.6	3.51
6-Me	22.6	1.76	2'	75.1	3.25
9-Me	22.7	0.85	5'	77.3	3.3 <sup>b</sup>
11-Me	24.1	0.63	3'	78.1	3.45
12	32.3	1.21, 1.84	13	78.1	3.52
9	34.5	1.54	15	80.2	3.83
11	38.0	1.33	1'	101.7	4.33
14	40.9	2.03	3	102.0	5.28
7a	42.4	1.68	7	124.4	5.01
8	43.6	0.84, 1.74	17	131.1	5.29
5	45.1	2.27	16	136.0	
2	45.6	3.22, 3.37	6	137.1	
11a	46.1	1.68	1	214.7	
10	47.5	0.91, 1.59			

Chemical shifts in ppm from TMS as an internal standard.

<sup>a</sup> These values may be interchanged.

<sup>b</sup> It is overlapped by solvent signal.

Table 3. The antimicrobial activities of aldecalmycin.

Test organism	MIC ( $\mu\text{g/ml}$ )	Test organism	MIC ( $\mu\text{g/ml}$ )
<i>Staphylococcus aureus</i> FDA 209P	6.25	<i>Corynebacterium bovis</i> 1810	12.5
<i>S. aureus</i> Smith	12.5	<i>Escherichia coli</i> NIHJ	> 100
<i>S. aureus</i> MS9610	6.25	<i>E. coli</i> K-12	> 100
<i>S. aureus</i> No. 5 (MRSA)	12.5	<i>Shigella dysenteriae</i> JS11910	> 100
<i>S. aureus</i> No. 17 (MRSA)	12.5	<i>Salmonella typhi</i> T-63	> 100
<i>Micrococcus luteus</i> FDA 16	12.5	<i>Proteus vulgaris</i> OX19	> 100
<i>M. luteus</i> IFO 3333	12.5	<i>Serratia marcescens</i>	> 100
<i>M. luteus</i> PCI 1001	50	<i>Pseudomonas aeruginosa</i> A3	> 50
<i>Bacillus anthracis</i>	6.25	<i>P. aeruginosa</i> GN315	100
<i>B. subtilis</i> NRRL B-558	6.25	<i>Klebsiella pneumoniae</i> PCI 602	> 100
<i>B. subtilis</i> PCI 219	6.25	<i>Mycobacterium smegmatis</i> ATCC 607	100
<i>B. cereus</i> ATCC 10702	6.25	<i>Candida albicans</i> 3147	100

Biological properties of aldecalmycin (**1**) are shown in Table 3. **1** shows the antimicrobial activities against Gram-positive bacteria including MRSA. The MICs of **1** against Gram-positive bacteria are 6.25~25  $\mu\text{g/ml}$ . The acute toxicity of **1** ( $\text{LD}_{50}$  in mice) was 100 mg/kg with iv administration.

RYUICHI SAWA  
YOSHIKAZU TAKAHASHI  
SAKIKO ITOH  
KAZUO SHIMANAKA  
NAOKO MATSUDA  
MASA HAMADA  
TSUTOMU SAWA

HIROSHI NAGANAWA  
TOMIO TAKEUCHI

Institute of Microbial Chemistry,  
3-14-23 Kamiosaki, Shinagawa-ku,  
Tokyo 141, Japan

(Received September 20, 1991)

#### Reference

- 1) HAYAKAWA, Y.; N. KANAMARU, N. MORISAKI, K. FURIHATA & H. SETO: Lydicamycin, a new antibiotic of a novel skeletal type II. Physico-chemical properties and structure elucidation. *J. Antibiotics* 44: 288~292, 1991